Sitagliptin in treatment of diabetes complicated by chronic hepatitis C.
Yanai
H
H
D001786:Blood Glucose / Q000378:metabolism; D015897:Comorbidity; D048909:Diabetes Complications / Q000453:epidemiology; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D005260:Female; D019698:Hepatitis C, Chronic / Q000453:epidemiology; D006801:Humans; D008875:Middle Aged; D011719:Pyrazines / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*
D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D011719:Pyrazines; D014230:Triazoles; D000068900:Sitagliptin Phosphate